Skip to main content

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) Investor Lawsuit Against Acquisition FiledCascadian Therapeutics Inc (USA)

  • Investors who purchased shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Lawsuit Overview

April 16, 2018 - The case was dismissed. February 13, 2018 - An investor in Cascadian Therapeutics, Inc.(Nasdaq:CASC) shares filed a lawsuit against the acquisition of Cascadian Therapeutics Inc by Seattle Genetics, Inc for $10.00 per share. The plaintiff alleges that the defendants breached their fiduciary duties owed to NASDAQ:CASC stockholders by agreeing to sell Cascadian Therapeu...



You must register (for free) or login to view the entire case.